A Multicenter Phase I Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) in Patients With Recurrent/Refractory Pediatric Solid Tumors (Ewing's Sarcoma, Desmoplastic Small Round Cell Tumor, Osteosarcoma, Neuroblastoma, and Rhabdomyosarcoma) and Leukemia

Inclusion Criteria:

- Histologically confirmed diagnosis of 1 of the following malignancies:

- Leukemia

- Lymphoid, myeloid, or mixed lineage

- Relapsed (in second or greater relapse) or refractory disease, confirmed by
1 of the following:

- Bone marrow relapse, defined as either M3 bone marrow (> 25% blasts
in the bone marrow aspirate) OR M2 bone marrow (5-25% blasts in the
bone marrow aspirate) at any time after complete remission is attained

- CNS relapse, defined as at least 5 WBC/mL by cytospin of any
cerebrospinal fluid (CSF) specimen OR less than 5 WBC/mL by cytospin
of 2 consecutive CSF specimens obtained >= 4 weeks apart and having
definitive confirmation that blasts are derived from the original
leukemic clone by molecular cytogenetics, multiparameter flow
cytometry, or immunostaining of >= 2 antigens

- Patients with underlying chronic myeloid leukemia must have > 25% blasts in
the bone marrow aspirate

- Patients with M3 bone marrow AND extramedullary sites of disease, other
than leptomeningeal disease, are eligible

- Solid tumor

- One of the following tumor types:

- Neuroblastoma

- Ewing's sarcoma

- Osteosarcoma

- Desmoplastic small round cell tumor

- Rhabdomyosarcoma

- Progressed after prior standard therapy OR no effective standard therapy
exists

- Measurable or nonmeasurable disease

- No known brain metastases

- No active leptomeningeal leukemia, defined by the following criteria:

- WBC > 5/mm^3 in cerebrospinal fluid (CSF)

- Unequivocal confirmation of leukemic blasts in CSF by cell morphology

- No symptomatic CNS disease (e.g., cranial nerve abnormalities) without cytologic
abnormality in CSF

- Performance status - Karnofsky 70-100% (for patients > 10 years of age)

- Performance status - Lansky 70-100% (for patients =< 10 years of age)

- More than 8 weeks

- Absolute neutrophil count >= 750/mm^3

- Platelet count >= 75,000/mm^3 (transfusion independent)

- Hemoglobin >= 8.5 g/dL (transfusion allowed)

- Bilirubin < 1.5 mg/dL

- ALT and AST =< 2.5 times upper limit of normal (ULN)

- INR =< 1.5 times ULN

- Albumin > 2.0 g/dL

- Creatinine =< 1.5 times ULN for age

- Creatinine clearance or radioisotope glomerular filtration rate > 60 mL/min

- Ejection fraction >= 50%

- Shortening fraction >= 28%

- QTc < 450 msec for men (470 msec for women)

- No congenital long QT syndrome

- LVEF > 40% by MUGA

- No symptomatic congestive heart failure

- No cardiac arrhythmia

- No New York Heart Association class III or IV heart failure

- No myocardial infarction within the past year

- No uncontrolled dysrhythmias

- No poorly controlled angina

- More than 12 months since active ischemic heart disease

- No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular
fibrillation >= 3 beats in a row)

- No left bundle branch block

- No other significant cardiac disease

- No pulmonary fibrosis by radiography

- No ongoing or active bacterial or fungal infection

- No other uncontrolled illness

- No psychiatric illness or social situation that would preclude study compliance

- No history of serious allergic reaction attributed to eggs or dimethyl sulfoxide

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Recovered from all immunotherapy

- At least 6 months since prior allogeneic stem cell transplantation

- At least 3 months since prior autologous stem cell transplantation

- At least 2 weeks since prior biologic agents (e.g., monoclonal antibodies)

- At least 1 week since prior filgrastim (G-CSF) or sargramostim (GM-CSF)

- Recovered from all prior chemotherapy

- At least 2 weeks since prior chemotherapy (for patients with leukemia only)

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
(for patients with solid tumors)

- No prior oxaliplatin

- No concurrent corticosteroids except for the treatment of adrenal crises in patients
with suppressed hypothalamic-pituitary-adrenal axis response OR for treatment of
allergic reactions to medications or blood products

- Recovered from all prior radiotherapy

- At least 6 months since prior radiotherapy to >= 50% of the pelvis

- At least 6 months since prior radiotherapy to substantial bone marrow, including
total body irradiation

- At least 4 weeks since prior local (small port) radiotherapy

- No prior radiotherapy to the heart

- At least 1 week since prior retinoids

- No concurrent antiretroviral therapy for HIV-positive patients

- No concurrent medication to control arrhythmias

- No concurrent medications that prolong or may prolong QTc interval

- No other concurrent investigational agents

- No other concurrent anticancer therapy